

**Table S3 | Clinical strains utilized in this study**

Strain	Colistin MIC (µg/mL)	Relevant characteristics	Reference or source
<b><i>Pseudomonas aeruginosa</i></b>			
<i>P. aeruginosa</i> LESB58	4	Liverpool Epidemic Strain isolate; colistin resistant	(1)
<i>P. aeruginosa</i> NZRM4034	1	Ceftazidime/piperacillin resistant isolate	ESR resources
<b><i>Acinetobacter baumannii</i></b>			
<i>A. baumannii</i> Ab5075	0.25	Virulent wound isolate	(2)
<i>A. baumannii</i> NZRM3289	1	Urine isolate (ATCC19606)	ESR resources
<i>A. baumannii</i> C4	37.5	Colistin-resistant isolate; phosphatidylethanolamine addition to lipid A	(3)
<b><i>Klebsiella pneumoniae</i></b>			
<i>K. pneumoniae</i> KPLN49	0.5	Vancouver General Hospital Isolate	(4)
<i>K. pneumoniae</i> NZRM4387	1	Extended spectrum β-lactamase urine isolate	ESR resources
<b><i>Enterobacter cloacae</i></b>			
<i>E. cloacae</i> 218R1	0.25	Class C β-lactamase overproducing strain	(5)
<b><i>Escherichia coli</i></b>			
<i>E. coli</i> E38 (serotype O78:H)	0.25	Human peritoneum isolate	BEI Resources
<i>E. coli</i> NZRM4403	0.5	β-lactamase overproducing human blood isolate	ESR resources
<i>E. coli</i> NCTC13846	3	Colistin resistant isolate; plasmid-borne mcr-1	(6)

## References

- (1) Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, *et al.* 1996. Spread of β-lactam-resistant *Pseudomonas aeruginosa* in a cystic fibrosis clinic. *Lancet* 348:639-642
- (2) Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, *et al.* 2014. AB5075, a highly virulent isolate of *Acinetobacter baumannii*, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. *mBio* 5:e01076-14
- (3) Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS *et al.* 2011. The pmrCAB operon mediates polymyxin resistance in *Acinetobacter baumannii* ATCC17978 and clinical isolates through phosphoethanolamine modification of lipid A. *Antimicrob Agents Chemother* 55:3732-3752
- (4) Behroozian S, Svensson SL, Davies J. 2016. Kisameet clay exhibits potent antibacterial activity against the ESKAPE pathogens. *mBio* 7:e01842-15
- (5) Marchou B, Bellido F, Charnas R, Lucain C, Pechere JC. 1987. Contribution of β-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in *Enterobacter cloacae*. *Antimicrob Agents Chemother* 32:1589095
- (6) Akhoundsadegh N, Belanger CR, Hancock REW. 2019. Outer Membrane Interaction Kinetics of New Polymyxin B Analogs in Gram-Negative Bacilli. *Antimicrob Agents Chemother* 63:277.